Unternehmensübersicht
ALX Oncology Holdings Inc. operates as a clinical-stage immuno-oncology entity dedicated to the development of novel therapies specifically designed for cancer patients within the United States. The company's primary strategic focus centers on Evorpacept, a CD47 blocking therapeutic biologic engineered to function as a combination therapy alongside other anti-cancer agents. This business model positions the firm within the broader healthcare sector, specifically the biotechnology industry, where capital allocation is directed toward advancing pre-clinical and clinical-stage candidates rather than commercializing established products. With a reported market capitalization of $268.48M and an employee base of 43 individuals, the company reflects the typical scale of a specialized biotech firm in the early development phase. The absence of reported annual revenue figures in the current financial snapshot indicates that the firm is likely deriving its primary cash flows from financing activities rather than commercial sales, which is characteristic of entities focused on late-stage clinical trials. The valuation metrics suggest that the market values the company's intellectual property and pipeline potential significantly more than its current operational cash generation, a dynamic common in biotechnology where future therapeutic approvals drive equity value.
Finanzielle Gesundheit
The financial statements for ALX Oncology Holdings Inc. reveal a net income of -$101,695,000 and an EBITDA of -$100,140,000 over the trailing twelve-month period, while revenue and sales figures remain unreported or negligible. The substantial gap between the reported revenue and the significant net loss underscores a cost structure dominated by research and development expenses, clinical trial costs, and general administrative overheads rather than cost of goods sold. Free cash flow stands at -$50,609,000, indicating that the company is consuming cash to fund its operations and pipeline advancement, which limits its current financial flexibility to self-funding without external capital raises. All three margin metrics—gross margin, operating margin, and profit margin—are recorded at 0.0%, reflecting the fact that the company has not yet generated revenue sufficient to calculate meaningful profitability percentages at this stage of development. The balance sheet presents a mix of liquidity and leverage, holding $44.79M in cash against $14.77M in debt, resulting in a debt-to-equity ratio of 56.85. Despite the presence of debt, the current ratio of 2.07 suggests that the company maintains a conservative short-term liquidity position relative to its immediate obligations. Return on Equity is reported at -145.7% and Return on Assets at -61.0%, metrics that mathematically reflect the heavy investment in intangible assets and the dilution of shareholder equity through the pursuit of high-risk clinical milestones rather than immediate profit generation.
Bewertungsanalyse
Valuation multiples for ALX Oncology Holdings Inc. present a mixed picture due to the lack of traditional profitability measures. The P/E ratio (TTM) is listed as N/A because of the negative earnings, while the forward P/E is calculated at -3.32, a metric that implies the market is pricing in a specific trajectory for future earnings that may eventually become positive or that the current valuation is heavily dependent on non-GAAP adjustments or pipeline value. The price-to-book ratio stands at 4.27, indicating that the market values the company at more than four times its net asset value, suggesting a significant premium assigned to the value of the drug candidates and the clinical team over the tangible book value. Alternative valuation metrics such as price-to-sales (N/A) and EV/EBITDA (-2.38) further highlight the speculative nature of the stock, as the negative EV/EBITDA ratio confirms that the company is currently burning cash without generating operational earnings to support enterprise value. The stock has traded between a 52-week low of $0.40 and a high of $2.66; without a specific current price input to calculate the exact percentage, the range demonstrates the high volatility inherent in small-cap biotechnology equities. The beta of 0.50 indicates that the stock's price volatility is significantly lower than the broader market benchmark, suggesting it moves less dramatically than the overall market index despite its speculative risk profile.
Growth & Income
Growth metrics for ALX Oncology Holdings Inc. show revenue growth (YoY) and earnings growth (YoY) as N/A, consistent with a company that has not yet achieved commercial revenue milestones. In the absence of positive earnings growth or revenue expansion, the company is in a phase where it reinvests all available capital into research and development rather than distributing dividends to shareholders. The dividend yield is N/A and the payout ratio is 0.0%, confirming that the firm follows a standard biotech strategy of retaining earnings to fund clinical trials and operational costs rather than providing income to investors. Consequently, the overall growth and income profile is defined entirely by the potential success of the Evorpacept candidate and other pipeline assets, with no current contribution to shareholder income through dividends or earnings per share growth. This reinvestment strategy is typical for clinical-stage companies where the path to profitability is contingent upon regulatory approval and successful commercialization of future therapies.